Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Shah Discusses Sequencing for MCL

November 18th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Dr. O'Connor on Recent FDA Approvals in MCL

November 15th 2017

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).

Dr. Epperla on Treatment Following Ibrutinib in MCL

November 1st 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

FDA Approves Acalabrutinib for Mantle Cell Lymphoma

October 31st 2017

The FDA has granted an accelerated approval to acalabrutinib as a treatment for adult patients with mantle cell lymphoma following at least 1 prior therapy.

Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCL

October 25th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Goy Shares Insight on Novel Therapies in MCL

October 25th 2017

Andre Goy, MD, discusses the excitement surrounding novel therapies on the horizon in MCL.

Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma

October 24th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Rituximab Maintenance After ASCT Prolongs Survival in MCL

October 19th 2017

Maintenance rituximab (Rituxan) following autologous stem-cell transplantation improved survival in younger patients with mantle cell lymphoma, according to the LyMa trial.

Dr. Epperla Discusses the Current Treatment of MCL

October 18th 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma.

Dr. Shah Discusses Autologous Transplant in MCL

October 18th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL

October 18th 2017

Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Dr. Eskelund on Outcomes of TP53-Mutated MCL

October 11th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

TP53 Predicts Poorer Survival in Mantle Cell Lymphoma

October 9th 2017

Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.

Observation After Diagnosis Viable Strategy for Some Patients With MCL

September 21st 2017

Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.

Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL

September 19th 2017

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

Ibrutinib Highly Active Against MCL in Pooled Analysis

September 19th 2017

In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.

Dr. Hamlin on Future Combination Strategies in the MCL Landscape

September 6th 2017

Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape

September 1st 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).

Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment

August 28th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).

Dr. Shah on Excitement With Venetoclax in Patients With MCL

August 22nd 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).